Axa S.A. Has $768,000 Stock Position in Kenvue Inc. (NYSE:KVUE)

Axa S.A. raised its position in shares of Kenvue Inc. (NYSE:KVUE) by 75.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 35,954 shares of the company’s stock after purchasing an additional 15,479 shares during the quarter. Axa S.A.’s holdings in Kenvue were worth $768,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in KVUE. Grove Bank & Trust raised its stake in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in Kenvue during the 4th quarter worth about $29,000. SRS Capital Advisors Inc. lifted its stake in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the period. Fortitude Family Office LLC boosted its position in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Asset Planning Inc acquired a new stake in Kenvue during the fourth quarter worth approximately $42,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 1.7 %

NYSE KVUE opened at $24.47 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The business has a fifty day simple moving average of $23.13 and a 200 day simple moving average of $22.56. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17. The firm has a market capitalization of $46.95 billion, a P/E ratio of 46.17, a PEG ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. During the same period last year, the firm earned $0.28 earnings per share. The firm’s revenue was down 3.9% on a year-over-year basis. On average, analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue’s payout ratio is 154.72%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on KVUE shares. Redburn Atlantic assumed coverage on Kenvue in a research note on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price target on the stock. Canaccord Genuity Group raised their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Citigroup upped their price objective on shares of Kenvue from $22.00 to $24.50 and gave the company a “neutral” rating in a report on Friday. Evercore ISI initiated coverage on Kenvue in a research note on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price for the company. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $25.25.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.